
## Haluk Yuzugullu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10992136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature Reviews Cancer, 2015, 15, 7-24.	28.4	1,083
2	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	16.8	356
3	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell, 2015, 163, 174-186.	28.9	346
4	Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Molecular Cancer, 2009, 8, 90.	19.2	171
5	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell, 2017, 31, 576-590.e8.	16.8	84
6	Senescence and immortality in hepatocellular carcinoma. Cancer Letters, 2009, 286, 103-113.	7.2	72
7	Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. Liver International, 2011, 31, 561-571.	3.9	64
8	Genome-Wide Transcriptional Reorganization Associated with Senescence-to-Immortality Switch during Human Hepatocellular Carcinogenesis. PLoS ONE, 2013, 8, e64016.	2.5	61
9	Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. Journal of Clinical Investigation, 2014, 124, 1794-1809.	8.2	48
10	A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications, 2015, 6, 8501.	12.8	44
11	NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways. Cell Discovery, 2016, 2, 16030.	6.7	17
12	Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2021, 52, 1356-1369.	1.3	2